- Clovis Oncology Inc (NASDAQ:CLVS) announced a presentation detailing initial Phase 1 data from Phase 1/2 LuMIERE clinical study of FAP-2286 labeled with lutetium-177 (177Lu-FAP-2286).
- Overall, in nine patients treated in the first two dose cohorts, 177Lu-FAP-2286 demonstrated a manageable safety profile and encouraging evidence of activity, including a confirmed RECIST partial response in one patient.
- A confirmed RECIST partial response was reported in one heavily pre-treated patient in the 3.7 GBq dose cohort who completed six administrations of 177Lu-FAP-2286.
- Related: Clovis Oncology Targeted Cancer Radiation Therapy Shows Greater Tumor Inhibition.
- A decrease in the serum tumor marker carcinoembryonic antigen was also observed in the patient over the 177Lu-FAP-2286 administration.
- Recruitment for the third dose cohort (7.4 GBq) is ongoing.
- The company updated the investigator-initiated Phase 1 study of FAP-2286 labeled with gallium-68 (68Ga-FAP-2286) as a novel imaging agent to identify metastatic cancer in patients with solid tumors.
- The safety and tumor uptake of the imaging agent 68Ga-FAP-2286 is being evaluated, with plans for Phase 2 expansion cohorts in multiple tumor types to initiate in Q4 2022.
- Price Action: CLVS shares are up 11.70% at $0.90 during the premarket session on the last check Wednesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Clovis Shares Jumps After Highlighting Data From Targeted Radiotherapy Trial
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks